Please assess the completion status of the following clinical trial:

Trial Title: Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. \> Age of 18 at time of first visit.~2. HIV uninfected~3. Willing and able to provide written informed consent.~4. Willing and able to provide adequate locator information.~5. Willing and able to return to all study visits.~6. Willing to participate in all study procedures.~7. Childbearing age: Willing to use contraception for as long as they are on study medication plus 7 days after. (Appendix A: list of approved contraception).~8. Possible sexual exposure to HIV-1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure. A possible exposure could include:~   1. Condomless anal, vaginal, oral, or mucosal (e.g. conjunctival) exposure to ejaculate from a partner who is HIV-1 infected or high risk for HIV infection and of unknown HIV-1 serostatus (may include protected sexual exposure with condom failure, breakage or slippage); or~  2. Condomless penile exposure to cervicovaginal secretions or anorectal secretions from a partner who is HIV-1 infected or high risk for HIV infection and of unknown HIV-1 serostatus (may include protected sexual exposure with condom failure, breakage or slippage)~Exclusion Criteria:~1. An active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures.~2. Pregnancy and/or breastfeeding.~3. People who are actively trying to become pregnant.~4. Acute or chronic hepatitis B infection.~5. Acute or chronic renal disease.~6. Creatinine clearance at or below 30 mL/min (Cockcroft-Gault0 Known intolerance or allergy to tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, or bictegravir.~8. Currently taking or plans to take prohibited medication while enrolled in the study. (Appendix B: complete list of prohibited medications).~9. Non-English speakers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Open Label Biktarvy (Type: EXPERIMENTAL): Single arm all participants receive open label study product intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).